Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients

Rheumatoid arthritis (RA) is a chronic inflammatory disease that preferentially affects joints, and characterized by an approximately two-fold increased risk of cardiovascular diseases compared with the general population. Beyond classical cardiovascular risk factors, systemic inflammatory markers are primarily involved. Hence, anti-inflammatory strategies such as homocysteine-lowering interventions are warranted. Indeed, hyperhomocysteinemia is commonly found in RA patients as a result of both genetic and non-genetic factors including older age, male gender, disease-specific features and disease-modifying antirheumatic drugs. Most importantly in the pathophysiology of hyperhomocysteinemia and its related cardiovascular diseases in RA, there is a bi-directional link between immuno-inflammatory activation and hyperhomocysteinemia. As such, chronic immune activation causes B vitamins (including folic acid) depletion and subsequent hyperhomocysteinemia. In turn, hyperhomocysteinemia may perpetrate immuno-inflammatory stimulation via nuclear factor ƙappa B enhancement. This chronic immune activation is a key determinant of hyperhomocysteinemia-related cardiovascular diseases in RA patients. Folate, a homocysteine-lowering therapy could prove valuable for cardiovascular disease prevention in RA patients in the near future with respect to homocysteine reduction along with blockade of subsequent oxidative stress, lipid peroxidation, and endothelial dysfunction. Thus, large scale and long term homocysteine-lowering clinical trials would be helpful to clarify the association between hyperhomocysteinemia and cardiovascular diseases in RA patients and to definitely state conditions surrounding folic acid supplementation. This article reviews direct and indirect evidence for cardiovascular disease prevention with folic acid supplementation in RA patients.

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic symmetric and erosive synovitis that preferentially affects peripheral joints. RA patients have an approximately two-fold increased risk of myocardial infarction, cerebrovascular events and deep venous thrombosis as well as a 60 % increased risk for cardiovascular diseases (CVD) compared with the general population [1–3]. Irrespective of traditional cardiovascular risk factors, systemic inflammatory mediators characteristic of RA are primarily involved [1].

Homocysteine is a sulfhydryl-containing amino acid mainly formed from the essential amino acid methionine. Its plasma concentration depends on age, sex, lifestyle factors-(coffee consumption, smoking, physical activity, alcohol)-, genetic mutations leading to a severely diminished activity of the enzymes involved in homocysteine catabolism, drugs and diseases interfering with its metabolism, and most importantly with B vitamins intake. Since B-group vitamins (folic acid, pyridoxine and cobalamine) are involved in homocysteine catabolism, their plasma levels are inversely associated with that of homocysteine [4]. Thus, hyperhomocysteinemia (HHcy) which refers to fasting plasma homocysteine concentrations ≥ 15 μM [4], is associated with decreased folate levels. HHcy is a well-known cardiovascular risk factor in the general population [4, 5], and in RA patients [6, 7].

Considering the CVD epidemic in RA patients and the important role of systemic inflammation, anti-inflammatory strategies such as homocysteine-lowering interventions appear necessary. This paper reviews direct and indirect evidence for CVD prevention with folic acid supplementation in RA patients.

HHcy is common among RA patients, as a consequence of both genetic and non-genetic factors associated with the disturbance of homocysteine metabolism [7–22]. Genetic risk factors are essentially represented by the methylenetetrahydrofolate reductase (MTHFR) 677C > T homozygous or heterozygous genotype which results in impaired homocysteine methylation to form methionine [8]. Whereas non-genetic factors include older age [9, 10], male gender [9, 10], RA-specific features [4, 7, 11–22], and disease-modifying antirheumatic drugs (DMARDs) [23–28] (Fig. 1).

Homocysteine metabolism and major factors associated with hyperhomocysteinemia in rheumatoid arthritis patients. MTHFR methylene tetrahydrofolate; CBS cystathione β synthase; BHMT betaine homocysteine methyltransferase; MS methionine synthase; Vit vitamin; DMARDs disease-modifying antirheumatic drugs. Vit B9 depletion owing to immuno-inflammatory activation, DMARDs, and gastrointestinal disturbance impairs the MTHFR vit B9-dependent remethylation pathway together with the MTHFR C677T mutation; vit B12 depletion owing to both immuno-inflammatory activation and gastrointestinal disturbance impairs the MS vit B12-dependent remethylation pathway; vit B6 depletion owing to immuno-inflammatory activation and gastrointestinal disturbance impairs the CBS vit B6-dependent transsulfuration pathway

Full size image

RA-specific features that influence the development of HHcy are mainly immuno-inflammatory activation together with extra-articular features (e.g., gastrointestinal disorders and kidney dysfunction), and their resultant B vitamins (folic acid, pyridoxine and cobalamine) deficiency [4, 7, 11–20]. Antiphospholipid (aPL) autoantibodies could contribute to a lesser extent [21, 22]. In particular, CD4⁺CD28⁻ cells found in RA patients produce interferon gamma (IFN-γ) [11–13]. The latter cytokine activates T helper 1 (Th1) cells that spill over pro-inflammatory cytokines (tumor necrosis factor alpha [TNF-α], interleukin-1 [IL-1], interleukin-6 [IL-6]) [11, 13]. These cytokines perpetually stimulate excess monocyte/macrophage production of reactive oxygen species (ROS) free radicals, thus causing cellular damage [11]. The net result is a long-term shift in immuno-inflammatory activation, with antioxidant enzymes overloaded by excess ROS [11–13]. Then, other oxidation-sensitive molecules such as B vitamins (including folate) are targeted by ROS [11], and rapid synthesis of deoxyribonucleic acid (DNA) occurs within immunocompetent cells [14]. Hence, both oxidative stress and increased mitosis account for B vitamins deficiency. This deficiency could be exacerbated by gastrointestinal disturbances [15–20]. Indeed, B vitamins are absorbed across the small and large intestinal mucosa through active transport and passive diffusion [15–19]. Concerning folic acid absorption, the dietary vitamin B9 is transported by the mucosal proton-coupled folate-transporter across the apical brush-border membrane of the bowel, whereas the vitamin B9 from commensal bacteria is predominantly absorbed in the colon [15, 16]. However, RA is associated with frequent occult gut inflammation (due to the combination of both intestinal immune activation and the use of anti-inflammatory agents) which alters the mucosal structure and permeability [15, 19]. Furthermore, decremented intestinal microbiota has been reported in RA patients [20]. Hence, gastrointestinal disorders may reduce folic acid uptake in RA populations. In turn, folic acid deficiency along with vitamins B₆ and B₁₂ deficiencies cause homocysteine accumulation, given that they are co-factors for homocysteine catabolism [4, 7]. Homocysteine may further accumulate in RA patients with co-morbid kidney dysfunction since kidneys are key organs for the metabolism of homocysteine [4]. On the other hand, Seriolo and collaborators observed significantly incremented serum homocysteine concentration in aPL-positive female RA patients compared to their aPL-negative RA counterparts and to non-RA controls (16.6 ± 5.6 mol/l vs 13.9 ± 5.1 mol/l and 9.3 ± 4.1 mol/l, respectively; p <0.01 and p <0.0001) [21]. This finding together with the high prevalence of aPL autoantibodies (28 %) in RA patients [22] is suggestive of the role of aPL in the elevation of plasma homocysteine in RA patients, but the mechanistic link is still obscure.

DMARDs, essentially methotrexate, cause HHcy via folate depletion [23–28]. This requires inhibition of dihydrofolate reductase-an enzyme involved in homocysteine remethylation pathway [8, 23, 24]. Noteworthy, the effect of methotrexate is exacerbated when it is combined with sulfasalazine [13], or in patients exhibiting the MTHFR 677C > T genotype [8].

In the general population

HHcy is independently associated with coronary, cerebrovascular, and peripheral arterial diseases, as well as deep veinous thrombosis in the general population [4, 5]. Three main pathophysiological changes intimately connected form the basis of HHcy-associated CVD [4, 29–33]: i) oxidative stress [4, 29–33], ii) rise in asymmetric dymethylarginine (ADMA) [31–33], iii) propensity for thrombosis [4, 7] (Fig. 2).

Mechanisms explaining homocysteine-related cardiovascular diseases at large. Dark arrow main mechanisms; dotted arrow minor mechanism. HHcy Hyperhomocysteinemia; NO nitric oxide; DNA deoxyribonucleic acid; ADMA asymmetric dymethyl arginine; ox-LDL oxidized low density lipoprotein cholesterol; CVD cardiovascular diseases. Through S-nitrosohomocysteine, ADMA and oxidative stress, HHcy reduces NO bioavailability, thus causing endothelial dysfunction. Under high propensity for coagulation (characterized by platelet adhesion and activation, production of clotting molecules, impaired fibrinolysis) that can be exacerbated by HHcy, endothelial dysfunction evolves towards atherothrombosis. Besides, HHcy-related oxidative stress increases ox-LDL production hence leading to formation of the atheromatous plaque which together with arterial smooth muscle cells proliferation trigger atherosclerosis. Atherosclerosis and atherothrombosis (completed atherosclerosis with ruptured plaque and thrombosis) lead to CVD

Full size image

In situations of HHcy, homocysteine generates potent ROS free radicals through auto-oxidization of its highly active sulfhydryl group [29]. Continuous exposure of endothelial cells to higher homocysteine concentrations inhibits glutathione peroxidase, an enzyme that normally protects them against oxidative stress [4]. Together, these results indicate that HHcy induces vascular oxidative stress. Considering the physiological synthesis of nitric oxide (NO) by endothelial cells, vascular oxidative stress is responsible for reduced NO bioavailability [4, 29]. Endothelium-dependent NO levels may be further decreased by the reaction of NO with homocysteine at higher plasma homocysteine concentrations to form S-nitroso-homocysteine [4]. Of special relevance, reduced NO bioavailability subsequently induces endothelial dysfunction given the beneficial effects of the latter molecule (vascular tone regulation, inhibition of platelet activation, adhesion and aggregation, modulation of smooth cell proliferation and of endothelial-leukocyte interaction) [4, 29, 30]. In parallel, HHcy may dramatically increase the plasma concentration of ADMA-an endogenous nitric oxide synthase (NOS) inhibitor-by stimulation of its synthesis and inhibition of dimethylarginine dymethylaminohydrolase, the principal enzyme responsible for ADMA clearance [31]. ADMA is formed after proteolysis of proteins containing methylated arginine residues. Protein-arginine methylation is facilitated by protein methyltransferase enzymes which use S-adenosylmethionine (SAM) as the methyl donor group; SAM being released by adenosine triphosphate-activated L-methionine following homocysteine methylation [31, 32]. Through endothelial NOS inhibition, ADMA stimulates vascular oxidative stress, and consequently reduces NO bioavailability [4, 33]. Besides, ADMA depletes endothelial cells; thus worsening impairment of NO levels [33]. Taken together, HHcy induces endothelial dysfunction by reduction of NO levels through oxidative stress, formation of S-nitroso-homocysteine and raised ADMA production [4, 29–33].

Remarkably, atherogenesis is a complex process which likely starts by endothelial dysfunction [29–35], an“impaired endothelium-dependent blood-vessel dilation in response to a stimulus” [34]. Indeed, biological markers of endothelial dysfunction (Intracellular adhesion molecule-1, vascular cell adhesion molecule- 1, and P-selectin) are raised within the endothelium in the initial phase of atherosclerosis [34, 35]. Besides, these molecules may promote monocytes entry into the arterial wall where they become macrophages subsequently capturing oxidized low density lipoprotein (ox-LDL) molecules [34]. The resultant atherosclerotic plaque progression is under control of elevated cytokines released by inflammatory cells including ox-LDL fed macrophages termed “foam cells” [34]. Concurrent vascular smooth-muscle cell proliferation reinforces the plaque, and matrix metalloproteinases produced contributes to elastin and collagen breakdown within the arterial wall. Subsequent vessel fissuring is accompanied by entry of coagulation factors and platelet adherence that result in thrombosis, the late phase of atherosclerosis [35]. Noteworthy, HHcy stimulates endothelial dysfunction [4, 29–33], and lipid peroxidation [29–33] through oxidative stress and raised ADMA production. Furthermore, ADMA induces and amplifies macrophage transformation to foam cells within the arterial wall [4], and vascular smooth-muscle-cell proliferation [4]. Moreover, HHcy predisposes to thrombosis through platelet adhesion/activation and elevated production of clotting molecules (von Willebrand factor, factor V, protein C, tissue factor, lipoprotein (a) bounded to fibrin) [4] that can enter fissured arteries as well as impaired thrombolysis. Taken collectively, it is likely that HHcy directly and indirectly stimulates the atherosclerotic process throughout its development from the beginning with endothelial dysfunction to the end with thrombosis and resultant ischemia.

Beyond these major mechanisms, epigenetics, in particular DNA hypomethylation resulting from S-Adenosylhomocysteine accumulation over SAM may still facilitate atherogenesis by promotion of vascular smooth-muscle-cell proliferation through an oxidative stress dependent pathway. This can be seen in cases of mild to moderate HHcy [36]. Additional triggers of atherosclerosis in HHcy patients include traditional cardiovascular risk factors, especially arterial hypertension and a pro-atherogenic lipid profile with raised ox-LDL that leads to endothelial dysfunction and macrophage activation to foam cells within the arterial wall [7].

In rheumatoid arthritis patients

RA is associated with a two-fold increased cardiovascular risk [1, 2] that persists after adjustment for traditional cardiovascular risk factors, suggesting the pivotal role of chronic inflammation [2]. More so, inflammatory biomarkers of cardiovascular risk less prevalent in the general population are more accurate in the course of RA [37, 38]. May it be the case for HHcy which is over two times more frequent in RA patients than in the general population (20–42 % versus 5–7 % for RA and general populations respectively) [29, 39]. However, only a few epidemiological studies have investigated the putative link between HHcy and CVD in RA populations (Table 1) [10, 21, 40–43]. In a prospective cohort including 235 RA patients prospectively followed up during a time frame of 6.5 year, fatal/non-fatal atherothrombotic events (myocardial infarction, ischemic heart disease, stroke, transient ischemic attack, deep vein thrombosis/pulmonary embolism) were all predicted by high homocysteine levels (OR = 1.96, 95 % CI 0.99–3.50, p = 0.05) after adjustment for age and sex [10]. In addition, high serum total homocysteine concentrations predicted cerebral white matter lesions-complications of cerebral microvascular disease- in Japanese RA women after adjustment for RA duration, serum triglycerides, serum high density lipoprotein cholesterol, and fasting plasma glucose (OR 1.35, 95 % CI: 1.12-1.63, p < 0.0001) [40].

The pathophysiology of HHcy-derived CVD in RA patients is largely uncharacterized. Nevertheless, indirect evidence from relevant observations in the general population together with the crucial role of inflammation push forward our understanding of the several derangements that may interact to cause or exacerbate it [6, 11, 12, 14, 21, 22, 36–38, 44–51]. They include: i) oxidative stress [12, 44] ii) chronic inflammation and immune activation [11, 14, 37, 38, 45] iii) propensity for a pro-atherogenic lipid profile [44–47] iv) poor disease status and severe radiological damage [6, 12, 38, 44] v) thrombophilia [21, 22, 38] vi) increase of plasma ADMA levels [14, 48] vii) osteoprotegerin [49] viii) genetic and epigenetic factors [36, 50, 51]. For details, see Table 2.

Unlike in the general population where oxidative stress, ADMA and a prothrombotic status are the main determinants of HHcy-dependent CVD, oxidative stress and long-term shift in immuno-inflammatory activation are central for the occurrence and worsening of HHcy-mediated CVD in RA [8]. In fact, excess ROS free radicals released by homocysteine oxidation can enhance the Nuclear Factor ƙappa B (NF-ƙB) activity already upregulated in RA patients considering NF-ƙB as the master regulator of expression of inflammation genes [11, 12, 50]. Resultantly, pro-inflammatory biomarkers are excessively released into the circulation, perpetuating immuno-inflammatory activation [11]. The high inflammatory burden collectively with oxidative stress promote excess lipid peroxidation to form ox-LDL [38, 50], markers of subclinical atherosclerosis in RA [47]. Lipid peroxidation is sustained and aggravated by a high disease activity, and activates the endothelium. Besides, ox-LDL molecules are captured by macrophages, becoming foam cells that maintain the atherosclerotic plaque progression through persistent cytokine production [6, 38]. Furthermore, TNF-α promotes vascular smooth-muscle-cell proliferation. Moreover, IL-1, IL-6 and TNF-α are procoagulant since they upregulate tissue factor (that can enter into the injured arterial wall) and trigger endothelial cells to become prothrombotic (alongside oxidative stress) [37, 38]. Additional prothrombotic markers in the RA population such as aPL could interact with homocysteine to cause thrombotic events [21, 22]. Hence, thrombosis-the late phase of atherosclerosis- might occur as a result of oxidative stress together with pro-inflammatory biomarkers’ activity and aPL. In brief, the bi-directional link between homocysteine and immuno-inflammatory activation [8, 11] well illustrates how HHcy could contribute to a persistent worsened high risk for CVD in RA patients.

In the general population

Dozens of studies assessing the benefits of folic acid supplementation on vascular disease have been conducted to date, initially on animal models. El-Swefi and collaborators observed a significant increase of plasma NO concentration in ovariectomized rats co-treated with folic acid and estradiol compared with ovariectomized and estradiol-treated groups (15.5 ± 2.8 μmol/l vs 9.4 ± 2.5 μmol/l and 15.5 ± 2.8 μmol/l vs 12.2 ± 3 μmol/l respectively; p < 0.05 for all comparisons). Additionally, folic acid co-treatment with estradiol resulted in 23 % inhibition of copper-induced lipoprotein oxidation in comparison with the ovariectomized non-treated group [52]. Likewise, addition of folic acid to a homocystine-rich diet concomitantly reduced the occurrence of damaged cerebral vessels and raised glucose transporter protein-1 (a marker of cerebral endothelial dysfunction since it facilitates glucose transport across blood brain barrier endothelium) plasma concentration in male Sprague–Dawley rats after eight weeks [53]. Moreover, vitamin therapy (B2 or B6 plus B9) intriguingly inhibited neurologic signs of ischemic cerebral attack (unbalance, ataxia, and convulsions) in spontaneously hypertensive stroke-prone rats [54]. Note that all those changes were paralleled by homocysteine lowering [52–54]. Taken together, folic acid supplementation and subsequent homocysteine lowering might inhibit oxidative stress (thus reducing lipid peroxidation) and reverse endothelial dysfunction, with a net benefit on cerebral vessels.

Along these lines, there is compelling evidence from general population studies that folate supplementation reduces the risk of incident cerebrovascular events (ischemic/hemorrhagic) [55, 56]. Of particular relevance, a recent meta-analysis of 26 randomized double-blind placebo-controlled studies including 58,804 subjects reported a strong trend in the reduction of future stroke risk of 7 % (RR 0.93, 0.86 to 1.00; p = 0.05) with folic acid supplementation [55]. Consistent with this finding, a large double blinded clinical trial published this year observed a reduced risk of first stroke attributed to the folic acid-enalapril combination therapy as compared to enalapril administered alone (2.7 % of participants in the enalapril–folic acid group vs 3.4 % in the enalapril alone group; hazard ratio 0.79; 95 % CI, 0.68-0.93) [57]. Low baseline folate levels and high baseline plasma homocysteine were the main tenants of this benefit [55, 56]. Contrariwise, folic acid supplements do not prevent incident coronary heart disease (CHD). This has been suggested by a meta-analysis of large-scale randomized placebo-controlled clinical trials held over a five-year period, and involving 35,603 participants with no heterogeneity between trials [58].

Furthermore, folic acid supplementation does not appear beneficial for secondary prevention of CVD [59–61]. In particular, recurrent stroke cannot be prevented with folate therapy [59]. Additionally, the Vitamins and Thrombosis (VITRO) randomized placebo-controlled double blind trial failed to demonstrate a reduced risk of secondary deep veinous thrombosis and pulmonary embolism after B vitamin therapy [60]. However, it is still inconclusive whether or not folic acid is effective for the prevention of CHD in persons with previous CVD [59, 61]. The meta-analysis by Mei and collaborators reported a lack of efficacy of folic acid supplementation in the prevention of recurrent CHD (0.94 [0.85–1.04]) [59], same as Qin and collaborators [61]. Nevertheless, these last authors whose meta-analysis detected a substantial heterogeneity among studies observed a trend towards reduced coronary revascularization risk when folic acid and moderate B₆ were co-supplemented. Therefore, the effect of folic acid supplementation on CHD is worthy of definite clarifications.

In total, with the exception of primary prevention of cerebrovascular events [52–57], current knowledge does not support the systematic supplementation of folic acid for CVD primary or secondary prevention in the general population [58–61]. It has been speculated that HHcy preferentially targets cerebral microvasculature [55]. This may explain why folic acid therapy works only on primary prevention of stroke. In addition, it is possible that cardiovascular changes progress independently of homocysteine level once established [62]. This observation can help understand why folic acid supplementation does not effect on the prevention of recurrent CVD. But why is there a disappointment with vitamin therapy between primary and secondary preventions of stroke? Folic acid effectiveness might be increased in the earliest phase of cerebrovascular disease rather than in the late phase [61]. Following this observation, a meta-analysis of 14 randomized double-blind placebo-controlled trials including 732 people reported an improvement of endothelial dysfunction as measured by vessel flow mediated dilation after four weeks of folic acid supplementation, and this effect seemed independent of serum homocysteine reduction [30]. These changes were paralleled by a sharp reduction of total homocysteine plasma concentration. The findings of this meta-analysis further support reparation of damaged endothelium by folic acid treatment independently of plasma homocysteine reduction.

In rheumatoid arthritis

In spite of the acknowledged cardiovascular derangements of HHcy in RA patients [10, 21, 40–43], we still lack data regarding the effectiveness of homocysteine-lowering strategies for CVD prevention in this population. Yet, almost all prospective studies have clearly demonstrated a reduction of all-cause CVD morbidity and mortality associated with methotrexate treatment [63–65], and this benefit is thought to be partly confounded by folic acid supplementation which lowers methotrexate-induced HHcy [23, 25–28]. Still, the methotrexate-folic acid combination resulted in a reduced mortality hazard ratio of 0.2, compared with 0.5 for methotrexate alone in a RA cohort probably because of homocysteine lowering via folic acid supplements [66]. Moreover, a follow-up study of RA patients showed a rise in plasma homocysteine after a low-dose methotrexate of 7.5-10 mg/week. Most importantly, homocysteine levels were negatively correlated with folic acid co-treatment [67]. Contrasting with sparse homocysteine-lowering published studies in RA patients is their high cardiovascular risk.

It is remarkable that RA patients have a 60 % increased risk of death from myocardial infarction and stroke compared with the general population [3], and a 48 % increased risk of incident myocardial infarction [68]. Folic acid depletion and subsequent HHcy-common in RA patients- partly explain this trend via excess immuno-inflammatory activation [7, 11, 12, 38, 45]. Furthermore, variations of plasma homocysteine may significantly predict atherosclerosis progression in RA patients [69]. Therefore, homocysteine-lowering strategies might be suitable to curtail the CVD ‘epidemic’ in RA populations.

Learning from general population and animal studies [55–57] and more than in the general population, folic acid supplements could reduce incident cerebrovascular events in the RA population as well if we consider their high propensity for HHcy and folate deficiency [55–57]. This hypothesis can be further supported by the central role of oxidative stress in HHcy-mediated cerebrovascular disease regardless of populations and species [4, 7, 52–54] together with the likelihood of folic acid to reverse oxidative stress both independently of and via homocysteine lowering [56, 69]. However, it is questionable whether or not the likely impact of folate therapy on the cerebral microvasculature of RA patients extends to coronary and other peripheral vessels. Extrapolating from general population meta-analysis addressing the benefits of vitamin therapy on extracerebral vessels [59, 61], the answer is a priori negative. Nonetheless, the positive response cannot be completely ruled out. Indeed, a meta-analysis of 10 randomized double-blind placebo-controlled clinical trials totalizing 2052 subjects reported a significant decrement of carotid intima-media thickness (CIMT) in relation with folic acid supplementation, and this benefit was greater among high CVD risk individuals, with larger homocysteine reduction and higher baseline CIMT values being strongest predictors [70]. Notably, CIMT is a reliable marker of atherosclerosis progression and a strong predictor of future cardiovascular events including CHD in both general and RA populations [71, 72]. Besides, RA patients are high CVD risk subjects [1, 3, 6, 68] with higher baseline CIMT values [72] that steeply rise partly because of HHcy [69]. Thus, it can be speculated that folic acid supplementation may also significantly reduce or delay atherosclerosis progression, consequently preventing all-cause CVD in RA patients.

Overall, folic acid supplementation is an effective anti-oxidant therapy which could directly and indirectly limit immuno-inflammatory activation and lipid peroxidation as well as repair endothelial damage through oxidative stress antagonism in RA patients. Furthermore, it may positively impact on atherosclerosis progression via plasma homocysteine decrement. In light of these observations, we put forward the hypothesis that it may offer therapeutic potentials for CVD prevention in RA patients in the near future. Large-scale and long-term clinical trials examining the impact of folic acid supplementation on CVD in RA populations will be very informative in this context. In particular, numerous questions should be clarified by the several randomized controlled trials underway [73]. Is folate supplementation really associated with CVD risk reduction in RA patients with or without CVD? To which extent can folate supplementation be beneficial for CVD prevention in RA patients? What is the precise mechanism underlying HHcy-related CVD in RA patients? What are optimal dosage and frequency for folate administration? If correct, our hypothesis could have sizeable public health implications in the issue of CVD in RA patients. While awaiting, CVD prevention through systematic supplementation with folic acid is desirable in both RA patients at high risk for HHcy/folic acid deficiency (e.g., those taking antifolate agents such as methotrexate and sulfasalazine, those who have a folate-deficient diet) and those with ascertained HHcy. A weekly folic acid dose of five milligrams has been proposed for those taking methotrexate [10], while other subjects might be given the current recommended nutrient intake for folates (1.4 mg week⁻¹) [9] in absence of a specific evidence-based recommended dose.

CVD may be prevented in RA patients via folic acid supplementation that potentially lowers plasma homocysteine levels and inhibits/repairs its cardiovascular health hazards. However, large-scale and long-term homocysteine-lowering clinical trials with folate are warranted to conclude on causality of the association between HHcy and CVD in RA and to definitely clarify conditions of folate supplementation for a cardiovascular issue. Anyway, systematic supplement with folic acid of all RA patients at high risk for folic acid deficiency/ HHcy or those with confirmed HHcy is desirable in order to prevent CVD.

ADMA:

Asymmetric dymethylarginine

aPL:

Antiphospholipid

CHD:

Coronary heart disease

CIMT:

Carotid intima-media thickness

CVD:

Cardiovascular diseases

DMARDs:

Disease-modifying antirheumatic drugs

DNA:

Deoxyribonucleic acid

HHcy:

Hyperhomocysteinemia

IFN-γ:

Interferon gamma

IL-1:

Interleukin 1

IL-6:

Interleukin 6

MTHFR:

Methylenetetrahydrofolate reductase

NF-ƙB:

Nuclear factor kappa B

NO:

Nitric oxide

NOS:

Nitric oxide synthase

OR:

Odds ratio

ox-LDL:

Oxidized low density lipoprotein

ROS:

Reactive oxygen species

SAM:

S-adenosylmethionine

TNF-α:

Tumor necrosis factor alpha

The authors are solely responsible for the manuscript preparation, for its intellectual content, and for the decision to submit it for publication. They did not receive any funding.

Affiliations

1. Division of Medicine, Sangmelima Referral Hospital, P.O. Box 890, Sangmelima, Cameroon

   • Mickael Essouma

2. Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa

   • Jean Jacques N. Noubiap

3. Medical Diagnostic Center, Yaoundé, Cameroon

   • Jean Jacques N. Noubiap

Corresponding author

Correspondence to Mickael Essouma.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ME conceived the plan of the review, drafted the manuscript, and revised it for its intellectual content. JJNN was involved in drafting and revised the manuscript. Both authors read and approved the final version of the manuscript.

Reprints and Permissions